CLAIM #43247 · Merck & Company Inc (MRK) · 2022Q4 earnings call · Feb 2, 2023 · due Dec 31, 2023
“It’s on -- we will be -- when we talk about starting 10 to 15 Phase 3 clinical trials, just in Oncology, this subcu program is a critical component to that and we will be starting those Phase 3 this year.”
Dean Li · President, Merck Research Labs
PENDING
graded after results covering Dec 31, 2023 are reported
Verify independently
SEC filings for MRK ↗ · Claim quote is verbatim from the 2022Q4 earnings call.